Physician profile
Elizabeth E Meier
NPI 1225712029
$938.84
in general payments reported to CMS, 2019-2025
11 companies · $666 in 2025
The $666 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $140 · 2024: $132 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.97 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $223.07 | 2023-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Vision Care, INC. | $141.42 | 2025 | |
| Alcon Vision LLC | $91.00 | 2025 | Tryptyr, Hydrus Microstent, Clareon Panoptix Pro |
| Thea Pharma INC. | $60.86 | 2024-2025 | Iyuzeh |
| Glaukos Corporation | $48.06 | 2025 | Idosetr |
| Harrow Eye, LLC | $44.56 | 2024-2025 | Vevye |
| Dompe US, INC. | $28.31 | 2025 | Oxervate |
| Amgen INC. | $24.47 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $24.18 | 2024 | Tyrvaya |
| Lkc Technologies, INC. | $12.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.